Dr Jean Bousquet, a renowned expert in pulmonary allergy, has delivered a keynote lecture on the next generation guideline for allergic rhinitis treatment and new combination drug for allergic rhinitis treatment.
Bukwang Pharmaceutical Co., Ltd. (“Bukwang”) has invited Dr. Jean Bousquet to the Korean Academy of Asthma, Allergy and Clinical Immunology to give keynote lecture on allergic rhinitis.
Dr. Jean Bousquet is a professor emeritus of Pulmonary Medicine at Montpellier University, France, who was the founder of ARIA (Allergic Rhinitis and Its Impact on Asthma). He is globally well-known scholar in pulmonary allergy therapeutic area and was Chairman of the WHO Global Alliance against Chronic Respiratory Diseases.
The lecture ‘Next-generation ARIA guideline’ addressed the problem of low compliance rate in allergic rhinitis patients and introduced the effectiveness of new combination drug, anti-histamine (azelastine) – steroid (fluticasone), in allergic rhinitis. The keynote lecture has also indicated that the new combination treatment will be recommended as a more effective treatment for allergic rhinitis compared to steroid mono treatment in the next revised guideline.
Bukwang representative said “It was very important and helpful to learn the update on global treatment trend and the effectiveness of combination therapy.” And also added “our new combination treatment will strengthen the company portfolio in pulmonary allergy area and the company will continue to look for innovative treatment option.”
Bukwang has in its portfolio products in pulmonary-allergy field such as azelastine (for allergic rhinitis) and original doxofylline (for asthma treatment). With the launching of azelastine and fluticasone combination new drug, the company is expanding its portfolio in the field.